<DOC>
	<DOC>NCT01407965</DOC>
	<brief_summary>Tissue kinetics of ertapenem and meropenem in fatty tissue, intraperitoneal fluid and plasma.</brief_summary>
	<brief_title>Pharmacokinetics of Carbapenem Antibiotics in Obese Patients.</brief_title>
	<detailed_description>The purpose of this study is to determine the free tissue kinetics of ertapenem and meropenem in fatty tissue and intraperitoneal fluid up to 24 hours after administration of the IMP.</detailed_description>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Hospitalized patients 18 years or older requiring elective surgical intervention (open or laparoscopic surgery) at intraabdominal organs BMI more or even 40 written informed consent BMI &lt; 40 pregnancy or lactation in women emergency surgery history of serious allergy or intolerance to βlactam antibiotics systemic antimicrobial therapy with ceftazidime (internal standard of highperformance liquid chromatography / mass spectrometry) within a 7 days period prior to study entry ongoing intraabdominal infections terminal illness severe diseases of the liver, e.g. cirrhosis of the liver with ALT or AST &gt; 6 x upper limit of normal (ULN) and bilirubin &gt; 3 x ULN severe renal insufficiency with a creatinine clearance ≤30 mL/min. neutrophil count &lt; 1000 cells/mm3 platelets &lt; 75000 cells/mm3 coagulation studies (INR) &gt; 1.5 x ULN ongoing chemotherapy and/or radiotherapy ongoing therapy with valproin acid (in case of ertapenem administration).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>obesity</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>ertapenem</keyword>
	<keyword>meropenem</keyword>
</DOC>